p120-catenin participates in the progress of gastric cancer through regulating the Rac1 and Pak1 signaling pathway

Oncology Reports
Tong-Fei LiXi Wang

Abstract

p120-catenin (p120), an E-cadherin regulator, has been implicated as central to a series of genetic and epigenetic changes that ultimately lead to tumor progression and metastasis. Ras-related C3 botulinum toxin substrate 1 (Rac1)and p21-activated kinases (PAKs) are effectors of p120. In the present study, we examined the expression of p120, Rac1 and Pak1 using immunohistochemistry in human gastric cancer tissues. Then, we used the gastric cancer SGC7901 and AGS cell lines to explore the possible mechanism of p120, Rac1 and Pak1 in the progress of gastric cancer. Western blotting was used to detect the expression of p120, Rac1 and Pak1 in the two cell lines. Next, p120 was silenced using p120 siRNA or overexpression of p120 by transfection of the plasmid p120 1A into the two cell types, western blotting was used to investigate the expression changes of Rac1 and Pak1. Furthermore, the effects of p120 siRNA-mediated knockdown or overexpression on the proliferation and invasive ability of gastric cancer cells were investigated using wound healing test and Matrigel invasion assays. The results showed that p120 was downregulated in both poorly differentiated group and well differentiated human gastric cancer. However, Rac1 and Pak1 ...Continue Reading

References

Mar 1, 1995·The Journal of Cell Biology·S ShibamotoM Takeichi
Aug 1, 1997·Molecular and Cellular Biology·Y TangJ Field
Jan 12, 2000·The Journal of Cell Biology·M A ThoresonA B Reynolds
Aug 10, 2000·The Journal of Cell Biology·N K NorenB Kreft
Sep 12, 2000·Nature Cell Biology·P Z AnastasiadisA B Reynolds
Apr 21, 2001·Molecular and Cellular Biology·J QuA Minden
Apr 16, 2002·The International Journal of Biochemistry & Cell Biology·Zahara M Jaffer, Jonathan Chernoff
Oct 18, 2002·Journal of Cellular Physiology·Rakesh Kumar, Ratna K Vadlamudi
Nov 8, 2002·American Journal of Physiology. Cell Physiology·Torry A TuckerLisa M Schwiebert
Dec 21, 2002·Differentiation; Research in Biological Diversity·Molly A Thoreson, Albert B Reynolds
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Sep 4, 2007·The International Journal of Biochemistry & Cell Biology·Teresa Gómez del PulgarJuan Carlos Lacal
Jun 22, 2010·Journal of Cellular Biochemistry·Lisa Epstein WongAudrey Minden
Apr 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·Christy C OngKlaus P Hoeflich
May 31, 2011·Frontiers in Bioscience (Landmark Edition)·Rajamani RathinamSuresh K Alahari
Jan 10, 2013·Asia-Pacific Journal of Clinical Oncology·Yong-jun WuQi Su
Apr 30, 2013·Cancer Letters·Zhen-yu Zhang, Hai-yan Ge

❮ Previous
Next ❯

Citations

Jul 21, 2016·Molecular and Cellular Biochemistry·Nirupama ChatterjeeGayatri Ramakrishna
Feb 3, 2021·International Journal of Molecular Sciences·Cristina Herrera-ParienteLeticia Moreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Jin FengZhong Li
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Gang LiuDianjun Gao
Experimental and Molecular Pathology
Pingxiang WuLi Liang
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Xiao-Xia WangJun-Nian Zheng
© 2021 Meta ULC. All rights reserved